A Contemporary Prognostic Nomogram For Men With Hormone Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis

[Guest guest]

http://www.medicalnewstoday.com/articles/91899.php

A Contemporary Prognostic Nomogram For Men With Hormone Refractory

Metastatic Prostate Cancer: A TAX327 Study Analysis

Main Category: Prostate / Prostate Cancer News

Article Date: 16 Dec 2007 - 0:00 PST

UroToday.com - The commentary on this nomogram and why it is unique:

1. It is the only nomogram to predict survival out to 5 years in men with

castration-resistant prostate cancer

2. It is the only nomogram validated in the current docetaxel era that

accounts for docetaxel treatment

3. Includes relevant patient-centered variables such as pain which are not

included in other nomograms

4. Includes novel and independent prognostic factors including PSA doubling

time, mode of progression at baseline, number of sites of disease in

addition to traditional risk factors.

5. Validated in multinational large data set. Plans underway to validate

this prospectively in ongoing phase III trials.

Written by

J. Armstrong, MD - Duke Comprehensive Cancer Center - Department of

Medicine, Division of Medical Oncology, as part of Beyond the Abstract on

UroToday.com. This initiative offers a method of publishing for the

professional urology community. Authors are given an opportunity to expand

on the circumstances, limitations etc... of their research by referencing

the published abstract.